Clinical trials: Metastatic Colorectal Cancer, completed
Colorectal Cancer
A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer
The purpose of this study is to evaluate the combination of panitumumab and Triflridine/Tipiracil (FTD/TPI; TAS-102) in patients with RAS wild-type metastatic colorectal cancer (CRC) refractory to standard chemotherapy…
- Trial name
- APOLLON (NCT02613221)
- Testing
- Panitumumab + TAS-102
- Where
- 32 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Takeda
Colon Rectal Cancer Duke Stage Stageval
A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer
A Pilot Trial of Pre-Operative Chemoradiotherapy Using Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®) Followed by Definitive Surgery in Patients With Localized (Non-Metastatic) Rectal Cancer
- Trial name
- NCT01310985
- Testing
- Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)
- Where
- Saudi Arabia
- Volunteers
- 15 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Tumors
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
- Trial name
- NCT00248404
- Testing
- NB1011
- Where
- 3 sites in United States, Canada
- Volunteers
- 155 people
- Sponsor
- Kiadis Pharma
Recurrent Breast Cancer, Recurrent Colon Cancer
Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
This pilot clinical trial studies comprehensive gene sequencing in guiding treatment recommendations in patients with metastatic or recurrent solid tumors.
- Conditions
- Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Breast Cancer
- Trial name
- NCT01987726
- Testing
- cytology specimen collection procedure, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Metastatic Colorectal Cancer
Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer
The overall objective of this study is to develop a novel couple-based mindfulness intervention aimed at reducing distress in patients with metastatic colorectal cancer (mCRC) and their partners.
- Trial name
- NCT05840263
- Testing
- Qualitative interview, Cognitive Interviews
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Colorectal Cancer, Colorectal Cancer Metastatic
A Study of Famitinib in Patients With Advanced Colorectal Cancer
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3, and it's anti-angiogenesis effect has been viewed in preclinical tests. Phase I study has shown that the toxicity is manageable.
- Conditions
- Colorectal Cancer, Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
- Trial name
- NCT01762293
- Testing
- Famitinib
- Where
- 2 sites in China
- Volunteers
- 154 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Colorectal Cancer
Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)
This study will compare the safety and efficacy of dalotuzumab (MK-0646) in combination with cetuximab and irinotecan in treating participants with wild type KRAS (wtKRAS) metastatic colorectal cancer (CRC) compared to cetuximab…
- Trial name
- NCT00614393
- Testing
- dalotuzumab, irinotecan hydrochloride, cetuximab
- Volunteers
- 558 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Neoplasms
A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer
This was a Phase 1, open-label, single-center study of CS-1008, an immunoglobulin G subclass 1 (IgG1) humanized monoclonal antibody, in subjects with advanced colorectal carcinoma who had received ≥ 1 prior chemotherapy regimen…
- Trial name
- NCT01220999
- Testing
- CS-1008
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- Ludwig Institute for Cancer Research
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
Phase II trial to study the effectiveness of hepatic arterial infusion plus chemotherapy in treating patients who have colorectal cancer metastatic to the liver.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastases, Recurrent Colon Cancer
- Trial name
- NCT00026234
- Testing
- floxuridine, dexamethasone, oxaliplatin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
A Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis
The purpose of this study is the increase of resection rate of primary cancer in rectal after short course radiotherapy without interrupt chemotherapy schedule during the period of chemotherapy.
- Trial name
- NCT01269229
- Testing
- folfox, short course Radiotherapy
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Yonsei University
Bladder Cancer, Breast Cancer
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer
- Trial name
- NCT00004095
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Northwestern University
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00056030
- Testing
- cetuximab, fluorouracil, leucovorin calcium
- Where
- 162 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Neoplasms
Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
The purpose of this study is to assess if Regorafenib in combination with best supportive care will slow down tumor progression and result in increased survival in patients with metastatic colorectal cancer.
- Trial name
- CONCUR (NCT01584830)
- Testing
- Regorafenib (BAY73-4506)
- Where
- 25 sites in China, Hong Kong and 3 more
- Volunteers
- 204 people
- Sponsor
- Bayer
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
This 2 arm study will compare the resection rate of liver metastases and safety of surgery in patients with metastatic colorectal cancer and primarily unresectable liver metastases receiving treatment with Avastin in combination…
- Trial name
- NCT00778102
- Testing
- 5-FU, Irinotecan, Leucovorin
- Where
- 19 sites in Austria, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as ursodiol, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00873275
- Testing
- bevacizumab, FOLFOX regimen, fluorouracil
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Metastatic Colorectal Cancer
Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva
Chemotherapy and bevacizumab is given for 4 months. Patients who have not progressed will continue with maintenance treatment with either bevacizumab (Avastin) alone, or bevacizumab and erlotinib (Tarceva).
- Trial name
- ACT (NCT00598156)
- Testing
- erlotinib (Tarceva), bevacizumab (Avastin)
- Where
- 15 sites in Denmark, Sweden
- Volunteers
- 249 people
- Sponsor
- Lund University Hospital
Metastatic Colon Cancer
Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial
This is a randomized phase II, open label, two arm study, evaluating the efficacy of panitumumab in combination with Trifluridine-Tipiracilas third line therapy, after a first line containing an anti-EGFR agent panitumumab(at…
- Trial name
- VELO (NCT05468892)
- Testing
- Trifluridine Tipiracil, Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX]
- Where
- 8 sites in Italy
- Volunteers
- 68 people
- Sponsor
- University of Campania Luigi Vanvitelli
Colorectal Cancer
Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma
This study was designed to evaluate the ability for G17DT to slow or arrest tumor growth in patients with refractory colon cancer who had been previously treated with an Irinotecan-based chemotherapy.
- Trial name
- CC6 (NCT02118064)
- Testing
- G17DT-Irinotecan
- Volunteers
- 161 people
- Sponsor
- Cancer Advances Inc.
Metastatic Colorectal Cancer
Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer
This is an open, multicenter phase II trial of therapy with a combination of cetuximab, and irinotecan every second week combined with a daily dose of everolimus to patients with metastatic colorectal cancer with Kirsten rat…
- Trial name
- ICE (NCT01387880)
- Testing
- Everolimus
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Herlev Hospital
Colorectal Cancer, Gastroesophageal Cancer
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer…
- Conditions
- Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
- Trial name
- NCT03798626
- Testing
- Gevokizumab, Bevacizumab, Modified FOLFOX6
- Where
- 34 sites in United States, Australia and 13 more
- Volunteers
- 167 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.